Skip to main content

Advertisement

SpringerLink
Log in

Elevation of soluble interleukin-2 receptor in patients with non-small cell lung cancer treated with gefitinib

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

We previously reported that plasma thromboxan B2, soluble P-selectin, and serum regulated on activation, normal T-cell expressed and secreted (RANTES) were elevated after gefitinib treatment. We hypothesized that gefitinib could activate T-lymphocytes via activated platelets, and so we measured serum levels of soluble interleukin-2 receptor (sIL-2R) in patients medicated with gefitinib.

Methods

Twenty-one patients with non-small cell lung cancer (NSCLC) were entered into this study. All patients received gefitinib over 2 weeks without severe adverse effects. Blood samples were withdrawn from all patients before and after the administration of gefitinib and plasma soluble P-selectin, serum RANTES, and serum sIL-2R were measured by enzyme-linked immunosolvent assay. In addition, we carried out the basic study of the interleukin-2 receptor (IL-2R) expression on CD4+ lymphocytes by RANTES.

Results

Plasma soluble P-selectin, serum RANTES, and serum sIL-2R levels increased significantly in patients receiving gefitinib treatment for 1 and 2 weeks. RANTES did not induce the expression of IL-2R on CD4+ lymphocyte. However, the anti-CD3 monoclonal antibody-induced expression of IL-2R was enhanced by the addition of RANTES.

Conclusion

Our finding indicated that lymphocytes were activated by gefitinib treatment. We think that sIL-2R elevation after gefitinib administration may be a factor positively effecting patients with NSCLC. It is deemed possible that the effect of gefitinib is induced not only by its blocking of the tyrosine kinase of epidermal growth factor receptor but also by antitumor immunity via its activation of T-cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  • Ciardiello F, Tortora G (2001) A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7:2958–2970

    PubMed  CAS  Google Scholar 

  • Frasci G, Panza P, Comella P, Nicolella GP, Natale M, Pacilo C, Gravina A, Caputi V, Botti G, Comella G (1997) Cisplatin, gemcitabine, and vinorelbine in locally advanced or metastatic non-small-cell lung cancer: a phase I study. Ann Oncol 8:1045–1048

    Article  PubMed  CAS  Google Scholar 

  • Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Fek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereilova A, Dong RP, Baselga J (2003) Multi institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237–2246

    Article  PubMed  CAS  Google Scholar 

  • Henderson BE, Ross RK, Pike MC (1991) Toward the primary prevention of cancer. Science 254:1131–1137

    Article  PubMed  CAS  Google Scholar 

  • Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2. J Clin Oncol 22:785–794

    Article  PubMed  CAS  Google Scholar 

  • Josimovic-Alasevic O, Feldmeier H, Zwingeberger K, Harms G, Hahn H, Shrisuphanunt M, Diamantstein T (1988) Interleukin-2 receptor in patients with localized and systemic parasitic diseases. Clin Exp Immunol 72:249–254

    PubMed  CAS  Google Scholar 

  • Junker K, Thomas M, Schulmann K, Klinke F, Bosse U, Muller KM (1997) Tumor regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment. J Cancer Res Clin Oncol 123:469–477

    Article  PubMed  CAS  Google Scholar 

  • Kameyoshi Y, Dorschner A, Mallet AI, Christophers E, Schroder J-M (1992) Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med 176:587–592

    Article  PubMed  CAS  Google Scholar 

  • Kanazawa S, Muramatsu M, Kinoshita Y, Yamaguchi K, Nomura S (2005a) Gefitinib has the potential of activating cell immunity against malignant cells. J Clin Oncol 23:3865–3867

    Article  Google Scholar 

  • Kanazawa S, Yamaguchi K, Kinoshita Y, Muramatsu M, Komiyama Y, Nomura S (2005b) Gefitinib affects functions of platelets and blood vessels via changes in the prostanoids balance. Clin Appl Thromb Hemost 11:429–434

    Article  CAS  Google Scholar 

  • Kawashima O, Kamiyoshihara M, Sakata S, Endo K, Saito R, Morishita Y (2000) The clinicopathological significance of preoperative serum-soluble interleukin-2 receptor concentrations in operable non-small-cell lung cancer patients. Ann Surg Oncol 7:239–245

    Article  PubMed  CAS  Google Scholar 

  • Komaki R, Scott C, Lee JS, Urtasun RC, Byhardt RW, Emami B, Andrac EJ, Asbell SO, Rotman M, Cox JD (1997) Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): comparison of RTOG 83-11 and RTOG 91-06. Am J Clin Oncol 20:435–440

    Article  PubMed  CAS  Google Scholar 

  • Lebeau B, Chastang CL, Brechot JM, Capron F, Dautzenberg B, Delaisements C, Mornet M, Brun J, Hurdebourcq JP, Lamarie E (1994) Subcutaneous heparin treatment increases survival in small cell lung cancer. Cancer 74:38–45

    Article  PubMed  CAS  Google Scholar 

  • Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139

    Article  PubMed  CAS  Google Scholar 

  • Marino P, Preatoni A, Fonticoli L, Parodi M, Tarolo GL (1990) Biomarkers and IL-2R in lung cancer. Recenti Prog Med 81:702–704

    PubMed  CAS  Google Scholar 

  • Maurer LH, Herndon JE II, Hollis DR, Aisner J, Carey RW, Skarin AT, Perry MC, Eaton WL, Zacharski LL, Hammond S, Green MR (1997) Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small cell lung cancer: a Cancer and Leukemia Group B study. J Clin Oncol 15:3378–3387

    PubMed  CAS  Google Scholar 

  • Murakami S, Hirayama R, Satomi A, Okubo K, Matsuki M, Sakata H, Tsuji Y (1997) Serum sIL-2R concentrations in patients with breast cancer. Breast Cancer 4:25–28

    Article  PubMed  Google Scholar 

  • Neal ZC, Yang JC, Rakhmilevich AL, Buhtoiarov IN, Lum HE, Imboden M, Hank JA, Lode HN, Reisfeld RA, Gillies SD, Sondel PM (2004) Enhanced activity of Hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin-2 therapy. Clin Cancer Res 10:4839–4847

    Article  PubMed  CAS  Google Scholar 

  • O’Rourke MA (1997) Historical review of trials with vinorelbine in non-small-cell lung cancer. Oncology 11:20–27

    Google Scholar 

  • Page A, Nakhle G, Mercier C, Verdant A, Page P, Dontigny L, Allard S, Gauthier JJ, Cossette R (1987) Surgical treatment of bronchiogenic carcinoma: the importance of staging in evaluating late survival. Can J Surg 30:96–99

    PubMed  CAS  Google Scholar 

  • Schrum S, Probst P, Fleischer B, Zipfel PF (1996) Synthesis of the CC-chemokines MIP-1alpha, MIP-1beta, and RANTES is associated with a type 1 immune response. J Immunol 157:3598–3604

    PubMed  CAS  Google Scholar 

  • Sieminska A (2004) The value of measuring the serum level of soluble interleukin-2 receptors in lung cancer patients. Pol Merkuriusz Lek 16:188–190

    CAS  Google Scholar 

  • Smith KA (1988) Interleukin-2: inception, impact, and implications. Science 240:1169–1176

    Article  PubMed  CAS  Google Scholar 

  • Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carrol K (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527–1537

    Article  PubMed  CAS  Google Scholar 

  • Waldmann TA (1986) The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science 232:727–732

    Article  PubMed  CAS  Google Scholar 

  • Woodburn JR (1999) The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82:241–250

    Article  PubMed  CAS  Google Scholar 

  • Yamaguchi K, Kanazawa S, Muramatsu M, Kinoshita S, Nomura S (2005) Elevation of plasma RANTES levels and prognosis in patients treated with gefitinib. J Clin Oncol 16S:244s

    Google Scholar 

  • Yano T, Yoshino I, Yokoyama H, Fukuyama Y, Takai E, Asoh H, Ichinose Y (1996a) The clinical significance of serum soluble interleukin-2 receptors in lung cancer. Lung Cancer 15:79–84

    Article  CAS  Google Scholar 

  • Yano T, Fukuyama Y, Yokoyama H, Takai E, Tanaka Y, Asoh H, Ichinose Y (1996b) Interleukin-2 receptors in pulmonary adenocarcinoma tissue. Lung Cancer 16:13–19

    Article  CAS  Google Scholar 

  • Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ Jr, Forcier RJ, Edwards R, Headley E, Kim SH, O’Donnell JR, O’Dell R, Tornyos K, Kwaan HC (1981) Effect of sodium warfarin on survival in small cell carcinoma of the lung. JAMA 245:831–835

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. First Department of Internal Medicine, Kansai Medical University, 10-15 Fumizono-cho, Moriguchi, Osaka, 570-8507, Japan

    Shigenori Kanazawa, Kazuyuki Yamaguchi & Mikiko Muramatsu

  2. Department of Neurology, Kansai Medical University, 10-15 Fumizono-cho, Moriguchi, Osaka, 570-8507, Japan

    Yoshimi Kinoshita

  3. Department of Clinical Sciences and Laboratory Medicine, Kansai Medical University, 10-15 Fumizono-cho, Moriguchi, Osaka, 570-8507, Japan

    Yutaka Komiyama

  4. Division of Hematology, Kishiwada City Hospital, 1001 Gakuhara-cho, Kishiwada, Osaka, 596-8501, Japan

    Shosaku Nomura

Authors
  1. Shigenori Kanazawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazuyuki Yamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yoshimi Kinoshita
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yutaka Komiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mikiko Muramatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shosaku Nomura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shosaku Nomura.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kanazawa, S., Yamaguchi, K., Kinoshita, Y. et al. Elevation of soluble interleukin-2 receptor in patients with non-small cell lung cancer treated with gefitinib. J Cancer Res Clin Oncol 132, 719–725 (2006). https://doi.org/10.1007/s00432-006-0120-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-006-0120-x

Keywords

Search

Navigation